ClinicalTrials.gg
CompletedNCT04370873Updated May 28, 2025Results posted

Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)

A Phase 1 interventional study of Frespaciguat and Placebo in Pulmonary Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed at 9 sites in 3 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 397 studies in Hypertension, Pulmonary with a site in United States — 73 open to participants now, 87 under way, 9 of them phase 3. Hypertension, Pulmonary · United States.

Enrollment
167th of 286
22 · median 30
Started
2020
with 9 others
Phase 1
28 of 397
5 open now
Registered
297th of 397
by date

Among the 397 studies in Hypertension, Pulmonary with a site in United States, this one is the 167th largest by enrollment of the 286 interventional ones that give a count, is one of 10 that started in 2020, is one of 28 in phase 1, and was the 297th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

73 of the 397 studies in Hypertension, Pulmonary with a site in United States are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 397 studies in Hypertension, Pulmonary with a site in United States, or all of them as a file.
02

Study summary

The primary objectives of this study are to assess the safety/tolerability and efficacy (by evaluating changes in pulmonary vascular resistance [PVR] and pulmonary blood volume [PBV]) of frespaciguat in participants with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The primary hypothesis is that 28 days of frespaciguat treatment is superior to placebo treatment in reduction of PVR.

Read the detailed description

Part 1 of this study will assess safety, tolerability, and PK of frespaciguat compared to placebo. Part 2 will assess safety, tolerability, PK, and changes in PVR and PBV of frespaciguat compared to placebo.

03

Conditions studied

  • Pulmonary Hypertension
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is male or female, from 40 to 80 years of age inclusive at the time of signing .
  • Be judged to have no untreated, health issue from other comorbidities based on medical history, physical examination, vital signs and performed at the screening visit(s)
  • Be judged to have no untreated, clinically significant health issue from other comorbidities based on laboratory safety tests performed at the screening visit(s)
  • Male participants are eligible to participate if they agree to the following during the intervention period and for at least 14 days, corresponding to time needed to eliminate study intervention(s) (eg, 5 terminal half-lives) plus an additional 90 days (a spermatogenesis cycle) after the last dose of study intervention. Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent or agrees to use unless confirmed to be azoospermic (vasectomized or secondary to medical cause
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: She is a woman of nonchildbearing potential (WONCBP) or is a and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis)
  • Have been diagnosed with mild to severe (COPD) according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) diagnostic criteria (postbronchodilator (FEV1)/ forced vital capacity (FVC) ratio \< 0.7)
  • Has Modified Medical Research Council (MMRC) Dyspnea Score in the range of 1 through 3 at screening
  • Be deemed clinically stable by the investigator
  • Be or have suspected Pulmonary Hypertension Group 3 in particular: COPD
  • Have a history of right heart catheterization (RHC) within 3 years of starting study medication demonstrating mean pulmonary artery pressure (mPAP) ≥ 25mmHg and pulmonary vascular resistance (PVR) ≥ 3.75 Woods units or 300 dynes/sec/cm or have an echocardiogram performed by the investigator (or appropriate designee) at screening or within 1 year of screening demonstrating pulmonary artery systolic pressure ≥ 38 mmHg (Part 1 only) or ≥ 50 mmHg (Part 2 only) in conjunction with one or more of the following: tricuspid regurgitation velocity >3 m/s or significant right heart enlargement and or reduced right heart function

Exclusion criteria

Exclusion Criteria:

  • Has pulmonary hypertension subtypes including the following according to Nice 2013 Clinical classification. This includes Group 1 Pulmonary arterial hypertension (PAH): Idiopathic PAH, Heritable PAH including Bone morphogenetic protein receptor type II (BMPR2), Activin A receptor type II-like kinase-1 (ALK1), endoglin, Sterile alpha motif domain-containing protein 9 (SMAD9), caveolin 1 (CAV1), potassium two-pore-domain channel subfamily K member 3 (KCNK3) and unknown, Drug and toxin-induced PAH, PAH associated with Connective tissue disease, infection, Portal hypertension, Congenital heart disease (unrepaired and not requiring repair or repaired simple cardiac defects at least 1year status post corrective surgery, with no residual shunt), Schistosomiasis, Chronic hemolytic anemia, Persistent pulmonary hypertension of the newborn (PPHN), and Pulmonary veno-occlusive disease (PVOD) and or pulmonary capillary hemangiomatosis (PCH); Group 2 Pulmonary hypertension owing to left heart diseases including Left ventricular Systolic dysfunction, Left ventricular Diastolic dysfunction, Valvular disease, Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies; Group 3 Pulmonary hypertension owing to lung diseases or hypoxia not associated with including Interstitial lung disease, Other pulmonary diseases with mixed restrictive and obstructive pattern, Sleep-disordered breathing (mild obstructive sleep apnea (OSA) may be permitted with sponsor consultation), Alveolar hypoventilation disorders. Chronic exposure to high altitude, Developmental abnormalities; Group 4 Pulmonary hypertension defined as Chronic thromboembolic pulmonary hypertension [CTEPH]); and Group 5 Pulmonary Hypertension with unclear multifactorial mechanisms including Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, Splenectomy, Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis, lymphangioleimyomatosis, neurofibromatosis, vasculitis, Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders, and Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental pulmonary hypertension.
  • Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic (not including chronic stable Hep B and C), immunological, renal, respiratory (not including PH-COPD), genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Is mentally or legally incapacitated, has significant emotional problems at the time of pre-study (screening) visit or expected during the conduct of the study or has a history of clinically significant psychiatric disorder of the last 5 years. Participants who have had situational depression may be enrolled in the study at the discretion of the investigator
  • Has a history of cancer () except adequately treated nonmelanomatous skin carcinoma or carcinoma in situ of the cervix or other malignancies which have been successfully treated with appropriate follow up and therefore unlikely to recur for the duration of the study, in the opinion of the investigator and with agreement of the Sponsor
  • Has a history of significant multiple and/or severe allergies (eg, food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (ie, systemic allergic reaction) to prescription or non-prescription drugs or food
  • Is positive for surface antigen (HBsAg) [acute infection] or HIV (participants with positive HBsAG that demonstrate low viral load (chronic stable infection) are permitted.
  • Part 2 only: Has known sensitivity to iodine or iodine containing products
  • Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit.
  • Has persistent or permanent atrial fibrillation with uncontrolled ventricular rate (participants with paroxysmal atrial fibrillation or controlled atrial fibrillation with no clinically significant arrhythmia may be allowed per the judgement of the investigator)
  • Has history of combined pulmonary fibrosis and emphysema (CPFE) or severe bullous emphysema. If no history, a confirmed negative high-resolution computerized tomography scan (HRCT) for these conditions needs to have been performed within last 2 ears.
  • Has an active respiratory infection (common cold, influenza, pneumonia, acute bronchitis) with lung function values ( and/or FEV1/FVC ratio) that do not meet eligibility range
  • Has a physical limitation that will inhibit the participant to effectively perform low intensity exercise testing (e.g. severe arthritis of the hip or knee)
  • Is unable to refrain from or anticipates the use of any medication, including prescription and nonprescription drugs or herbal remedies beginning approximately 2 weeks (or 5 half-lives) prior to administration of the initial dose of study drug, throughout the study (including washout intervals between treatment periods), until the poststudy visit. There may be certain medications that are permitted
  • Is currently on monotherapy calcium channel blockers as a specific treatment for pulmonary hypertension
  • Is currently taking nitrates, inhaled prostacyclin, immediate or extended release diltiazem, phosphodiesterase 5 (PDE5) inhibitors or soluble guanylate cyclase (sGC) or activators for the treatment of pulmonary hypertension. Participants previously using medications to treat pulmonary arterial hypertension may be enrolled provided they have been off therapy for at least 2 weeks prior to the start of the screening period
  • Has participated in another study within 4 weeks (or 5 half-lives, whichever is greater) prior to the prestudy (screening) visit. The window will be derived from the date of the last visit in the previous study
  • Has FEV1 \< 30% predicted based on Pulmonary Function Tests (PFTs) at screening
  • Part 2 only: Does not meet RHC criteria at baseline
  • Participant has an estimated of \< 60 mL/min based on the Cockcroft Gault equation at screening
  • Suffers from claustrophobia and is unable to undergo a computerized tomography (CT) scan
  • Has participated in a positron emission tomography (PET) research study or other research study involving administration of a radioactive substance or ionizing radiation within 12 months prior to the screening visit or has undergone or plans to have extensive radiological examination within the period with a radiation burden over 10 millisievert (mSv)
  • Does not agree to follow the smoking restrictions as defined by the clinical research unit (CRU)
  • Consumes greater than 3 glasses of alcoholic beverages
  • Consumes excessive amounts, defined as greater than 6 servings of coffee, tea, cola, energy drinks, or other caffeinated beverages per day
  • Is a regular user of cannabis, any illicit drugs or has a history of drug (including alcohol) abuse within approximately 12 months. Participants must have a negative urine drug screen (UDS) prior to randomization
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Part 1: Frespaciguat

    Participants receive frespaciguat 360 μg once daily (QD) via inhalation from Days 1-7. Following review of pharmacokinetic (PK) and safety data, a second 7 days of dosing may be initiated. A dose of up to 360 μg up to twice a day may be administered based on PK data in these participants.

    Drug: Frespaciguat

  • Placebo comparator
    Part 1: Placebo

    Participants receive placebo QD via inhalation from Days 1-7.

    Drug: Placebo

  • Experimental
    Part 2: Frespaciguat

    Participants receive frespaciguat 32 µg, 100 µg, 195 µg or 380 μg QD via inhalation from Days 1-28.

    Drug: Frespaciguat

  • Placebo comparator
    Part 2: Placebo

    Participants receive placebo QD via inhalation from Days 1-28.

    Drug: Placebo

Interventions

  • Frespaciguat 32 µg, 100 µg, 195 µg, 360 µg or 380 µg administered as dry powder inhalation according to randomization. Following review of pharmacokinetic (PK) and safety data, a second 7 days of dosing may be initiated. A dose of up to 360 μg up to twice a day may be administered based on PK data. Dosage may be adjusted downwards in Part 2, if indicated by PK results in Part 1.

    Also known as: MK-5475

  • DrugPlacebo

    Placebo administered as dry powder inhalation according to randomization

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experienced at Least 1 Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE was assessed.

    Time frame: Up to approximately 139 days

  2. Percentage of Participants Who Discontinued Study Drug Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued treatment due to an AE was assessed.

    Time frame: Up to approximately 32 days

  3. Percentage Change From Baseline to Day 28 in Pulmonary Vascular Resistance (PVR): Part 2

    PVR was calculated in participants after MK-5475 dosing at baseline and Day 28. Based on the variables obtained by right heart catheterization (RHC), the fold change from baseline individual PVR was calculated. The difference from baseline was assessed on the log scale and then back-transformed for reporting (percent change from baseline). Per protocol, this outcome measure was only assessed during the Part 2 and was not assessed during part 1.

    Time frame: Baseline (between Day -5 and Day -1) and Day 28

Secondary outcomes

  1. Plasma Area Under the Concentration Time-Curve From 0 to Infinity (AUC0-inf) of MK-5475: Part 1

    Blood samples were taken predose and at specified times postdose to determine the AUC0-inf of MK-5475. Plasma AUC0-inf was defined as the area under the concentration vs. time curve for MK-5475 from 0 to infinite hours.

    Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose

  2. Plasma Area Under the Concentration Time-Curve From 0 to 24 Hours (AUC0-24) of MK-5475: Part 1

    Blood samples were taken predose and at specified times postdose on Day 7 to determine the AUC0-24 of MK-5475. AUC0-24 values for Day 1 correspond to extrapolated values since collection on Day 1 stopped at 8 hours.

    Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose

  3. Maximum Observed Plasma Concentration (Cmax) of MK-5475: Part 1

    Plasma concentration of MK-5475 was quantified for each arm to determine Cmax.

    Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose

  4. Plasma Concentration 24 Hours Postdose (C24) of MK-5475: Part 1

    Blood samples were taken to determine the C24 of MK-5475. Data are reported as Mean with Standard Deviation. Concentration values below the lower limit of quantification were treated as having a value of 0.

    Time frame: 24 hours postdose on Day 7

  5. Time to Maximum Concentration (Tmax) of MK-5475: Part 1

    Blood samples were taken at predose and at specified time points postdose to determine the Tmax of MK-5475. Tmax was defined as the time to maximum concentration of MK-5475.

    Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose

  6. Plasma Apparent Terminal Half-Life (t½) of MK-5475: Part 1

    Blood samples were taken at predose and at specified time points postdose to determine the t½ of MK-5475.

    Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose

  7. Cmax Accumulation Ratio of MK-5475: Part 1

    Blood samples were taken predose and at specified times postdose to determine the Cmax accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 Cmax to the Day 1 Cmax.

    Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose

  8. AUC0-24 Accumulation Ratio of MK-5475: Part 1

    Blood samples were taken predose and at specified times postdose to determine the AUC0-24 accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 AUC0-24 to the Day 1 AUC0-24.

    Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose

  9. AUC0-inf Accumulation Ratio of MK-5475: Part 1

    Blood samples were taken predose and at specified times postdose on Days 1-7 to determine the AUC0-inf accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 AUC0-inf to the Day 1 AUC0-inf.

    Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose

  10. AUC0-inf of MK-5475: Part 2

    Blood samples were taken pre-dose and at specified times post-dose to determine the AUC0-inf of MK-5475. Concentrations for samples collected pre-RHC in a time window of 6-8 hours postdose on Day 28 were used to derive PK parameter values on Day 28. A nominal elapsed time of 6.01 hours postdose was used in the calculation.

    Time frame: Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose

  11. AUC0-24 of MK-5475: Part 2

    Blood samples were taken predose and at specified times postdose on Day 28 to determine the AUC0-24 of MK-5475. Concentrations for samples collected pre-RHC in a time window of 6-8 hours postdose on Day 28 were used to derive PK parameter values on Day 28. A nominal elapsed time of 6.01 hours postdose was used in the calculation. AUC0-24 was calculated using extrapolated concentration at 24 hours postdose.

    Time frame: Day 28: Predose, 0.5, 1, 2 and 3 hours postdose

  12. Cmax of MK-5475: Part 2

    Blood samples were taken predose and at specified times postdose to determine the Cmax of MK-5475.

    Time frame: Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose

  13. Plasma Concentration 24 Hours Postdose (C24) of MK-5475: Part 2

    Blood samples were taken to determine the C24 of MK-5475. Data are reported as Mean with Coefficient of Variation, but due to data entry limitations the table below labels them as Geometric Mean and Geometric Coefficient of Variation. Concentration values below the lower limit of quantification were treated as having a value of 0.

    Time frame: 24 hours postdose on Day 7

  14. Tmax of MK-5475: Part 2

    Blood samples were taken predose and at specified times postdose to determine the Tmax of MK-5475.

    Time frame: Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose

  15. t½ of MK-5475: Part 2

    Blood samples were taken predose and at specified times postdose to determine the t½ of MK-5475.

    Time frame: Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose

  16. AUC0-3 Accumulation Ratio of MK-5475: Part 2

    Blood samples were taken predose and at specified times postdose on to determine the AUC0-3 accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 AUC0-3 to the Day 1 AUC0-3.

    Time frame: Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose

  17. Cmax Accumulation Ratio of MK-5475: Part 2

    Blood samples were taken predose and at specified times postdose to determine the Cmax accumulation ratio of MK-5475. Cmax accumulation ratio is the ratio of the Day 7 Cmax to the Day 1 Cmax.

    Time frame: Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 15: 1 hour postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose

  18. Percent Change From Baseline in Pulmonary Blood Volume (PBV) at Day 28: Part 2

    Participants underwent a series of computed tomography (CT) scans with an intravenous (IV) iodinated contrast agent to facilitate assessment of PBV at baseline and at several times points after MK-5475 dosing. Percentage change from baseline (CFB) in PBV was calculated and reported for each dose group that underwent FRI in Part 2. As pre-specified, central tendency for PBV percentage CFB was provided as numerical values rounded to whole numbers. Per protocol, this outcome measure was only assessed during the Part 2 FRI Period for each panel and was not assessed during part 1 and part 3.

    Time frame: Baseline (between Day -5 and Day -1) and Day 28

07

Results

Posted Apr 26, 2024

Participant flow

Adult participants with pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (COPD) were recruited to evaluate safety, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of MK-5475.

Part 1: 7-day Dosing
Participant flow — Part 1: 7-day Dosing
MilestonePart 1: MK-5475 360 μgPart 1: PlaceboPart 2: MK-5475 380 μgPart 2: Placebo
Started6300
Completed6300
Not completed0000
Part 2: 28-day Dosing
Participant flow — Part 2: 28-day Dosing
MilestonePart 1: MK-5475 360 μgPart 1: PlaceboPart 2: MK-5475 380 μgPart 2: Placebo
Started0085
Completed0085
Not completed0000

Outcome measures

PrimaryPercentage of Participants Who Experienced at Least 1 Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE was assessed.

Time frame:
Up to approximately 139 days
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experienced at Least 1 Adverse Event (AE)
Percentage of ParticipantsPart 1: MK-5475 360 μgPart 1: PlaceboPart 2: MK-5475 380 μgPart 2: Placebo
Percentage of Participants Who Experienced at Least 1 Adverse Event (AE)33.333.333.380.0
PrimaryPercentage of Participants Who Discontinued Study Drug Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued treatment due to an AE was assessed.

Time frame:
Up to approximately 32 days
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Discontinued Study Drug Due to an AE
Percentage of ParticipantsPart 1: MK-5475 360 μgPart 1: PlaceboPart 2: MK-5475 380 μgPart 2: Placebo
Percentage of Participants Who Discontinued Study Drug Due to an AE0.00.00.00.0
PrimaryPercentage Change From Baseline to Day 28 in Pulmonary Vascular Resistance (PVR): Part 2

PVR was calculated in participants after MK-5475 dosing at baseline and Day 28. Based on the variables obtained by right heart catheterization (RHC), the fold change from baseline individual PVR was calculated. The difference from baseline was assessed on the log scale and then back-transformed for reporting (percent change from baseline). Per protocol, this outcome measure was only assessed during the Part 2 and was not assessed during part 1.

Time frame:
Baseline (between Day -5 and Day -1) and Day 28
Reported as:
Mean · Percentage change
Percentage Change From Baseline to Day 28 in Pulmonary Vascular Resistance (PVR): Part 2
Percentage changePart 2: MK-5475 380 μgPart 2: Placebo
Percentage Change From Baseline to Day 28 in Pulmonary Vascular Resistance (PVR): Part 2-21.23 ± 16.98-5.39 ± 49.21
SecondaryPlasma Area Under the Concentration Time-Curve From 0 to Infinity (AUC0-inf) of MK-5475: Part 1

Blood samples were taken predose and at specified times postdose to determine the AUC0-inf of MK-5475. Plasma AUC0-inf was defined as the area under the concentration vs. time curve for MK-5475 from 0 to infinite hours.

Time frame:
Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
Reported as:
Geometric mean · hr*nM
Plasma Area Under the Concentration Time-Curve From 0 to Infinity (AUC0-inf) of MK-5475: Part 1
hr*nMPart 1: MK-5475 360 μg
Day 13.32 ± 68.9
Day 74.03 ± 90.2
SecondaryPlasma Area Under the Concentration Time-Curve From 0 to 24 Hours (AUC0-24) of MK-5475: Part 1

Blood samples were taken predose and at specified times postdose on Day 7 to determine the AUC0-24 of MK-5475. AUC0-24 values for Day 1 correspond to extrapolated values since collection on Day 1 stopped at 8 hours.

Time frame:
Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
Reported as:
Geometric mean · hr*nM
Plasma Area Under the Concentration Time-Curve From 0 to 24 Hours (AUC0-24) of MK-5475: Part 1
hr*nMPart 1: MK-5475 360 μg
Day 13.31 ± 68.7
Day 74.22 ± 83.5
SecondaryMaximum Observed Plasma Concentration (Cmax) of MK-5475: Part 1

Plasma concentration of MK-5475 was quantified for each arm to determine Cmax.

Time frame:
Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
Reported as:
Geometric mean · nM
Maximum Observed Plasma Concentration (Cmax) of MK-5475: Part 1
nMPart 1: MK-5475 360 μg
Day 10.830 ± 50.8
Day 70.970 ± 59.1
SecondaryPlasma Concentration 24 Hours Postdose (C24) of MK-5475: Part 1

Blood samples were taken to determine the C24 of MK-5475. Data are reported as Mean with Standard Deviation. Concentration values below the lower limit of quantification were treated as having a value of 0.

Time frame:
24 hours postdose on Day 7
Reported as:
Mean · nM
Plasma Concentration 24 Hours Postdose (C24) of MK-5475: Part 1
nMPart 1: MK-5475 360 μg
Plasma Concentration 24 Hours Postdose (C24) of MK-5475: Part 10.02 ± 0.3
SecondaryTime to Maximum Concentration (Tmax) of MK-5475: Part 1

Blood samples were taken at predose and at specified time points postdose to determine the Tmax of MK-5475. Tmax was defined as the time to maximum concentration of MK-5475.

Time frame:
Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
Reported as:
Median · Hours
Time to Maximum Concentration (Tmax) of MK-5475: Part 1
HoursPart 1: MK-5475 360 μg
Day 11.00 (1.00 to 2.00)
Day 71.00 (1.00 to 2.00)
SecondaryPlasma Apparent Terminal Half-Life (t½) of MK-5475: Part 1

Blood samples were taken at predose and at specified time points postdose to determine the t½ of MK-5475.

Time frame:
Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
Reported as:
Geometric mean · Hours
Plasma Apparent Terminal Half-Life (t½) of MK-5475: Part 1
HoursPart 1: MK-5475 360 μg
Day 12.13 ± 18.5
Day 72.81 ± 48.4
SecondaryCmax Accumulation Ratio of MK-5475: Part 1

Blood samples were taken predose and at specified times postdose to determine the Cmax accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 Cmax to the Day 1 Cmax.

Time frame:
Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
Reported as:
Geometric mean · Ratio
Cmax Accumulation Ratio of MK-5475: Part 1
RatioPart 1: MK-5475 360 μg
Cmax Accumulation Ratio of MK-5475: Part 11.17 ± 28.8
SecondaryAUC0-24 Accumulation Ratio of MK-5475: Part 1

Blood samples were taken predose and at specified times postdose to determine the AUC0-24 accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 AUC0-24 to the Day 1 AUC0-24.

Time frame:
Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
Reported as:
Geometric mean · Ratio
AUC0-24 Accumulation Ratio of MK-5475: Part 1
RatioPart 1: MK-5475 360 μg
AUC0-24 Accumulation Ratio of MK-5475: Part 11.27 ± 30.1
SecondaryAUC0-inf Accumulation Ratio of MK-5475: Part 1

Blood samples were taken predose and at specified times postdose on Days 1-7 to determine the AUC0-inf accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 AUC0-inf to the Day 1 AUC0-inf.

Time frame:
Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
Reported as:
Geometric mean · Ratio
AUC0-inf Accumulation Ratio of MK-5475: Part 1
RatioPart 1: MK-5475 360 μg
AUC0-inf Accumulation Ratio of MK-5475: Part 11.21 ± 31.1
SecondaryAUC0-inf of MK-5475: Part 2

Blood samples were taken pre-dose and at specified times post-dose to determine the AUC0-inf of MK-5475. Concentrations for samples collected pre-RHC in a time window of 6-8 hours postdose on Day 28 were used to derive PK parameter values on Day 28. A nominal elapsed time of 6.01 hours postdose was used in the calculation.

Time frame:
Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose
Reported as:
Geometric mean · hr*nM
AUC0-inf of MK-5475: Part 2
hr*nMPart 2: MK-5475 380 μg
Day 1NA ± NA
Day 281.98 ± 105.9
SecondaryAUC0-24 of MK-5475: Part 2

Blood samples were taken predose and at specified times postdose on Day 28 to determine the AUC0-24 of MK-5475. Concentrations for samples collected pre-RHC in a time window of 6-8 hours postdose on Day 28 were used to derive PK parameter values on Day 28. A nominal elapsed time of 6.01 hours postdose was used in the calculation. AUC0-24 was calculated using extrapolated concentration at 24 hours postdose.

Time frame:
Day 28: Predose, 0.5, 1, 2 and 3 hours postdose
Reported as:
Geometric mean · hr*nM
AUC0-24 of MK-5475: Part 2
hr*nMPart 2: MK-5475 380 μg
Day 1NA ± NA
Day 281.97 ± 105.7
SecondaryCmax of MK-5475: Part 2

Blood samples were taken predose and at specified times postdose to determine the Cmax of MK-5475.

Time frame:
Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose
Reported as:
Geometric mean · nM
Cmax of MK-5475: Part 2
nMPart 2: MK-5475 380 μg
Day 10.348 ± 48.4
Day 280.397 ± 71.4
SecondaryPlasma Concentration 24 Hours Postdose (C24) of MK-5475: Part 2

Blood samples were taken to determine the C24 of MK-5475. Data are reported as Mean with Coefficient of Variation, but due to data entry limitations the table below labels them as Geometric Mean and Geometric Coefficient of Variation. Concentration values below the lower limit of quantification were treated as having a value of 0.

Time frame:
24 hours postdose on Day 7

No measurements were reported for this outcome.

SecondaryTmax of MK-5475: Part 2

Blood samples were taken predose and at specified times postdose to determine the Tmax of MK-5475.

Time frame:
Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose
Reported as:
Median · Hours
Tmax of MK-5475: Part 2
HoursPart 2: MK-5475 380 μg
Day 11.50 (1.00 to 2.00)
Day 281.50 (1.00 to 2.00)
Secondaryt½ of MK-5475: Part 2

Blood samples were taken predose and at specified times postdose to determine the t½ of MK-5475.

Time frame:
Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose
Reported as:
Geometric mean · Hours
t½ of MK-5475: Part 2
HoursPart 2: MK-5475 380 μg
Day 1NA ± NA
Day 282.06 ± 62.4
SecondaryAUC0-3 Accumulation Ratio of MK-5475: Part 2

Blood samples were taken predose and at specified times postdose on to determine the AUC0-3 accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 AUC0-3 to the Day 1 AUC0-3.

Time frame:
Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose
Reported as:
Geometric mean · Ratio
AUC0-3 Accumulation Ratio of MK-5475: Part 2
RatioPart 2: MK-5475 380 μg
AUC0-3 Accumulation Ratio of MK-5475: Part 21.11 ± 53.8
SecondaryCmax Accumulation Ratio of MK-5475: Part 2

Blood samples were taken predose and at specified times postdose to determine the Cmax accumulation ratio of MK-5475. Cmax accumulation ratio is the ratio of the Day 7 Cmax to the Day 1 Cmax.

Time frame:
Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 15: 1 hour postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose
Reported as:
Geometric mean · Ratio
Cmax Accumulation Ratio of MK-5475: Part 2
RatioPart 2: MK-5475 380 μg
Cmax Accumulation Ratio of MK-5475: Part 21.14 ± 51.6
SecondaryPercent Change From Baseline in Pulmonary Blood Volume (PBV) at Day 28: Part 2

Participants underwent a series of computed tomography (CT) scans with an intravenous (IV) iodinated contrast agent to facilitate assessment of PBV at baseline and at several times points after MK-5475 dosing. Percentage change from baseline (CFB) in PBV was calculated and reported for each dose group that underwent FRI in Part 2. As pre-specified, central tendency for PBV percentage CFB was provided as numerical values rounded to whole numbers. Per protocol, this outcome measure was only assessed during the Part 2 FRI Period for each panel and was not assessed during part 1 and part 3.

Time frame:
Baseline (between Day -5 and Day -1) and Day 28
Reported as:
Mean · Percentage Change
Percent Change From Baseline in Pulmonary Blood Volume (PBV) at Day 28: Part 2
Percentage ChangePart 2: MK-5475 380 μgPart 2: Placebo
Percent Change From Baseline in Pulmonary Blood Volume (PBV) at Day 28: Part 2-0.3 ± 4.7-2.8 ± 10.6

Adverse events

Collected over Up to approximately 139 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK-5475 360 µg (Part 1)0/6 (0%)0/6 (0%)2/6 (33.3%)
Placebo (Part 1)0/3 (0%)0/3 (0%)1/3 (33.3%)
MK-5475 380 µg (Part 2)0/9 (0%)1/9 (11.1%)2/9 (22.2%)
Placebo (Part 2)0/5 (0%)1/5 (20%)4/5 (80%)
Most frequent serious events
Most frequent serious events
EventMK-5475 360 µg (Part 1)Placebo (Part 1)MK-5475 380 µg (Part 2)Placebo (Part 2)
Cardiac failureCardiac disorders0/60/30/91/5
COVID-19Infections and infestations0/60/31/90/5
COVID-19 pneumoniaInfections and infestations0/60/31/90/5
EncephalopathyNervous system disorders0/60/31/90/5
Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders0/60/31/90/5
Most frequent other events
Most frequent other events
EventMK-5475 360 µg (Part 1)Placebo (Part 1)MK-5475 380 µg (Part 2)Placebo (Part 2)
HeadacheNervous system disorders2/61/30/90/5
Lacrimation increasedEye disorders0/60/30/91/5
Urinary tract infectionInfections and infestations0/60/30/91/5
Accidental overdoseInjury, poisoning and procedural complications0/60/30/91/5
Blood creatinine increasedInvestigations0/60/30/91/5
DizzinessNervous system disorders0/60/30/91/5
AgitationPsychiatric disorders0/60/31/91/5
Infusion site extravasationGeneral disorders0/60/31/90/5

Baseline characteristics

One participant in Part 1 also participated in Part 2. That participant is counted only in Part 1 for baseline characteristics.

Age, Continuous
Age, Continuous(Years)Part 1: MK-5475 360 μgPart 1: PlaceboPart 2: MK-5475 380 μgPart 2: PlaceboTotal
Mean62.2 ± 12.762.3 ± 8.769.4 ± 4.866.6 ± 5.665.8 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: MK-5475 360 μgPart 1: PlaceboPart 2: MK-5475 380 μgPart 2: PlaceboTotal
Female12003
Male518519
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: MK-5475 360 μgPart 1: PlaceboPart 2: MK-5475 380 μgPart 2: PlaceboTotal
Hispanic or Latino00000
Not Hispanic or Latino638522
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: MK-5475 360 μgPart 1: PlaceboPart 2: MK-5475 380 μgPart 2: PlaceboTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White638522
More than one race00000
Unknown or Not Reported00000
Pulmonary Vascular Resistance (PVR): Part 2
Pulmonary Vascular Resistance (PVR): Part 2(dynes*s*cm^-5)Part 1: MK-5475 360 μgPart 1: PlaceboPart 2: MK-5475 380 μgPart 2: PlaceboTotal
Mean——409.52 ± 166.47394.32 ± 141.18404.46 ± 152.08
08

Study locations

9 sites
  • Lexington VA- Health Care System ( Site 0034)
    Lexington, Kentucky 40502, United States
  • Johns Hopkins - University ( Site 0003)
    Baltimore, Maryland 21205, United States
  • Massachusetts General Hospital ( Site 0005)
    Boston, Massachusetts 02114, United States
  • Brigham & Women's Hospital ( Site 0001)
    Boston, Massachusetts 02115, United States
  • University of Rochester Medical Center ( Site 0012)
    Rochester, New York 14642, United States
  • Medical Universtiy of South Carolina ( Site 0011)
    Charleston, South Carolina 29425, United States
  • Rambam Medical Center ( Site 0037)
    Haifa, 3109601, Israel
  • Rabin Medical Center ( Site 0035)
    Petah Tikva, 4941492, Israel
  • Republican Clinical Hospital of Moldova ( Site 0013)
    Chisinau, 2025, Moldova, Republic of
09

References and documents

Publications

  • Bajwa EK, Cislak D, Kumar A, Li D, Messina EJ, Reynders T, Denef JF, Corcea V, Buch KP, Lai E, Stoch SA. Phase 1 Study of MK-5475, an Inhaled Soluble Guanylate Cyclase Stimulator, in Participants with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2024 May 23;19:1105-1121. doi: 10.2147/COPD.S454905. eCollection 2024. PubMed 38803412 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Jan 2022, 19 months.

Results were first posted in Apr 2024, 2 years 3 months after primary completion.

Of 21 phase 1 interventional studies under Hypertension, Pulmonary, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 19 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2020
First posted
May 1, 2020
StartActual
Jun 5, 2020
Primary completionActual
Jan 12, 2022
CompletionActual
Jan 12, 2022
Results first posted
Apr 26, 2024
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04370873
Responsible party
Sponsor
First posted
May 1, 2020
Start date
Jun 5, 2020
Primary completion
Jan 12, 2022
Completion
Jan 12, 2022
Results posted
Apr 26, 2024
Last update
May 28, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Frespaciguat

Start the discussion